Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Research Partnership Seeks Compounds to Slow Loss of Motor Neurons in ALS

By BiotechDaily International staff writers
Posted on 01 Oct 2013
Print article
A renowned American research institute is collaborating with a German drug discovery company to identify compounds that can prevent or slow down the loss of motor neurons, which is characteristic of the human disease amyotrophic lateral sclerosis (ALS).

ALS is a debilitating disease that induces muscle weakness and atrophy throughout the body caused by the degeneration of the upper and lower motor neurons. The majority of ALS victims die within three to five years from the onset of the symptoms, and only about 10% survive for 10 years or more. The incidence of the syndrome is approximately two per 100,000 people, and there are about 150,000 diagnosed ALS patients worldwide.

Investigators at the Harvard Stem Cell Institute (Boston, MA, USA) will be working with colleagues at Evotec AG (Hamburg, Germany) in a strategic partnership dedicated to the identification of compounds able to prevent or slow down the loss of motor neurons in ALS. The collaboration, which is being called “CureMN” (CureMotorNeuron), will leverage human motor neuron assays based on ALS patient-derived induced pluripotent stem (iPS) cells that were developed by Harvard Stem Cell Institute researchers Dr. Lee Rubin and Dr. Kevin Eggan.

Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies. Evotec has established an enviable position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuroscience, pain, metabolic diseases as well as oncology and inflammation.

Dr. Cord Dohrmann, CSO of Evotec, said, “Kevin and Lee have made significant contributions to our understanding of the underlying pathology of motor neuron diseases. Their laboratories have developed a large array of ALS patient-derived motor neuron models that allow screening of diseased human cells in culture – an approach that is sometimes referred to as a “clinical trial in a dish.” Our intention is to systematically screen for new mechanisms, targets, and compounds that have the potential to be developed into new products that will modify and ideally halt the progression of ALS and potentially other motor neuron diseases.”

Related Links:
Harvard Stem Cell Institute
Evotec AG



Print article

Channels

Drug Discovery

view channel
Image: A scanning electron microscope (SEM) image of methicillin-resistant Staphylococcus aureus bacteria (Photo courtesy of the CDC).

Drug Combination Cures MRSA Infection While Preventing Development of Resistance

Treatment with a combination comprising the well-known antibiotic cefdinir and the experimental drug TXA709 cured mice of drug-resistant staphylococcal infections while reducing the development of resistance.... Read more

Biochemistry

view channel
Image: A space-filling model of the anticonvulsant drug carbamazepine (Photo courtesy of Wikimedia Commons).

Wastewater May Contaminate Crops with Potentially Dangerous Pharmaceuticals

Reclaimed wastewater used to irrigate crops is contaminated with pharmaceutical residues that can be detected in the urine of those who consumed such produce. Investigators at the Hebrew University... Read more

Lab Technologies

view channel
Image: A three-dimensional printer adapted for stem cell production (Photo courtesy of Nano Dimension).

Israeli Developers Demonstrate Prototype Three-Dimensional Bioprinter

Two Israeli companies have combined efforts in the development of three-dimensional printer technology for the production of stem cells. The three-dimensional print electronics developer Nano Dimension... Read more

Business

view channel

Acquisition to Boost Development of Drugs for Neurogenic Conditions

According to a recent announcement, a privately held biotechnology/drug development company is to be acquired by one of the major pharmaceutical manufacturers. The drug manufacturer Merck & Co. (Kenilworth, NJ, USA) has agreed to pay 500 million USD up front for Afferent Pharmaceuticals (San Mateo, CA, USA) and up... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.